Merck & Co., Inc. (MRK)
NYSE • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Merck & Co., Inc. currently loses $8.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 26 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Merck & Co. beat revenue expectations in the second fiscal quarter of 2026, based on preliminary results reported Aug. 4, as revenue rose about 5% to about $16.6 billion from $15.8 billion a year ago and came in ahead of the $16.37 billion consensus by about 2%. Gross profit reached roughly $12.2 billion, and gross margin held near 74%, giving the quarter a largely margin-supported profile. Operating cash flow came to about $5.4 billion, while the company repurchased about $757 million of stock and paid about $2.14 billion in dividends. Consensus for the next period calls for EPS of $2.27 on revenue of $17.29 billion.
Next report — what to expect
Merck & Co., Inc. (MRK) reports on October 29, 2026. The next-period consensus calls for EPS of $2.20 on revenue of $17.31 billion. As trailing context, revenue grew +5.1% year over year last quarter. Merck has beaten EPS in 7 of 8 most recent quarters, a key point to watch against expectations.
About Merck & Co., Inc.
Merck & Co., Inc., listed on the NYSE under MRK, develops and markets human and animal health products as a global biopharmaceutical company. It operates in the drugmaking business, with FY2025 revenue of $64.9 billion, through a Pharmaceuticals segment focused on medicines and vaccines for people and an Animal Health segment serving veterinary care and livestock markets.
Today's Snapshot
MRK closed slightly higher at 144.31, in line with a flat sector. Shares changed hands at about two-thirds of its usual level. Merck reported trial results, prompting Scotiabank, an investment bank, to raise its price target.
Trading Volume
Below 10d avg (8.7M)
5.4M
vs S&P 500 Today
Moderate Underperformance
-0.43%
Updated: October 2, 2026 at 20:15 UTC
MRK Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$123.20 - $146.58Buy
- RSI (14)46.27Neutral
- Stochastic %K (14, 3, 3)19.14Buy
- MACD Level (12, 26)0.71Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.